Profile data is unavailable for this security.
About the company
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
- Revenue in USD (TTM)30.26m
- Net income in USD-149.24m
- Incorporated2003
- Employees165.00
- LocationMarinus Pharmaceuticals IncThree Radnor Corporate Center100 Matsonford Rd, Suite 304RADNOR 19087United StatesUSA
- Phone+1 (484) 801-4670
- Fax+1 (302) 655-5049
- Websitehttps://marinuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexaria Bioscience Corp | 411.01k | -4.85m | 51.54m | 5.00 | -- | 5.09 | -- | 125.40 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 57.53m | 134.00 | 4.86 | 0.2302 | 1.76 | 0.2234 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Qilian International Holding Group Ltd | 29.87m | -7.86m | 58.25m | 298.00 | -- | 1.33 | -- | 1.95 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| SCYNEXIS Inc | 9.67m | -35.39m | 60.19m | 29.00 | -- | 0.9965 | -- | 6.23 | -0.735 | -0.735 | 0.2005 | 1.60 | 0.0736 | -- | 0.7011 | 333,344.80 | -26.95 | -30.02 | -31.99 | -36.35 | -55.82 | -- | -366.09 | -86.76 | -- | -- | 0.1747 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| United-Guardian, Inc. | 12.31m | 3.25m | 66.80m | 25.00 | 20.58 | 5.51 | 19.94 | 5.43 | 0.7065 | 0.7065 | 2.68 | 2.64 | 0.9575 | 4.12 | 7.65 | 492,387.20 | 25.25 | 29.84 | 28.67 | 34.39 | 50.66 | 55.31 | 26.37 | 28.79 | 6.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| Journey Medical Corp | 77.68m | 843.00k | 74.37m | 58.00 | 50.30 | 8.95 | 18.14 | 0.9574 | -0.0131 | -0.0131 | 3.91 | 0.5642 | 1.15 | 2.36 | 5.71 | 1,339,328.00 | 1.25 | -- | 5.17 | -- | 66.79 | -- | 1.09 | -- | 1.08 | 2.00 | 0.6682 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -29.10m | 74.41m | 43.00 | -- | 7.75 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Verrica Pharmaceuticals Inc | 13.91m | -86.93m | 75.52m | 100.00 | -- | -- | -- | 5.43 | -1.88 | -1.88 | 0.3001 | -0.3133 | 0.2436 | -- | 2.68 | 139,080.00 | -152.23 | -55.75 | -196.62 | -78.33 | 84.02 | -- | -625.06 | -754.94 | 2.23 | -12.96 | 1.42 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Cellectar Biosciences Inc | 0.00 | -50.98m | 75.64m | 20.00 | -- | 7.70 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Marinus Pharmaceuticals Inc | 30.26m | -149.24m | 85.38m | 165.00 | -- | -- | -- | 2.82 | -2.66 | -2.66 | 0.5391 | -0.8614 | 0.21 | 0.7508 | 6.98 | 183,412.10 | -103.54 | -49.64 | -131.60 | -57.76 | 90.64 | -- | -493.14 | -518.96 | 2.15 | -11.80 | 6.10 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 88.16m | 220.00 | -- | 0.3751 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.22m | 35.00 | 391.37 | 348.44 | -- | 35.38 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 23.10m | -27.21m | 92.34m | 176.00 | -- | 10.24 | -- | 4.00 | -2.03 | -2.03 | 1.72 | 0.6731 | 0.3577 | 0.8917 | 2.39 | 131,250.00 | -41.56 | -34.75 | -62.38 | -46.91 | 56.81 | 55.98 | -116.17 | -153.72 | 2.36 | -- | 0.6718 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Rockwell Medical Inc | 94.37m | -4.77m | 119.44m | 237.00 | -- | 5.20 | -- | 1.27 | -0.169 | -0.169 | 3.21 | 0.7573 | 2.07 | 13.97 | 11.61 | 398,194.10 | -10.48 | -46.29 | -16.25 | -65.38 | 13.44 | 4.66 | -5.06 | -36.51 | 1.60 | -1.84 | 0.3144 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
Data as of Sep 18 2024. Currency figures normalised to Marinus Pharmaceuticals Inc's reporting currency: US Dollar USD
48.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Jun 2024 | 4.80m | 8.71% |
| Woodline Partners LPas of 30 Jun 2024 | 3.98m | 7.23% |
| Suvretta Capital Management LLCas of 30 Jun 2024 | 3.82m | 6.94% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 3.49m | 6.34% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.78m | 5.06% |
| Lion Point Capital LPas of 30 Jun 2024 | 2.11m | 3.84% |
| Bleichroeder LPas of 30 Jun 2024 | 1.87m | 3.40% |
| Jennison Associates LLCas of 30 Jun 2024 | 1.47m | 2.67% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.36m | 2.47% |
| abrdn, Inc.as of 30 Jun 2024 | 1.08m | 1.96% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
